334 related articles for article (PubMed ID: 20656333)
1. Increased circulating procoagulant activity and thrombin generation in patients with myeloproliferative neoplasms.
Duchemin J; Ugo V; Ianotto JC; Lecucq L; Mercier B; Abgrall JF
Thromb Res; 2010 Sep; 126(3):238-42. PubMed ID: 20656333
[TBL] [Abstract][Full Text] [Related]
2. Platelet-induced thrombin generation by the calibrated automated thrombogram assay is increased in patients with essential thrombocythemia and polycythemia vera.
Panova-Noeva M; Marchetti M; Spronk HM; Russo L; Diani E; Finazzi G; Salmoiraghi S; Rambaldi A; Barbui T; Ten Cate H; Falanga A
Am J Hematol; 2011 Apr; 86(4):337-42. PubMed ID: 21442635
[TBL] [Abstract][Full Text] [Related]
3. ADP-induced platelet aggregation and thrombin generation are increased in Essential Thrombocythemia and Polycythemia Vera.
Panova-Noeva M; Marchetti M; Russo L; Tartari CJ; Leuzzi A; Finazzi G; Rambaldi A; ten Cate H; Falanga A
Thromb Res; 2013 Jul; 132(1):88-93. PubMed ID: 23735588
[TBL] [Abstract][Full Text] [Related]
4. [Detection and clinical significance of JAK2 mutation in 412 patients with chronic myeloproliferative neoplasms].
Chao HY; Fan Z; Zhang R; Shen YM; Chen W; Fei HR; Zhu ZL; Feng YF; Chen ZX; Xue YQ
Zhonghua Zhong Liu Za Zhi; 2009 Jul; 31(7):510-4. PubMed ID: 19950698
[TBL] [Abstract][Full Text] [Related]
5. Markers of myeloproliferative diseases in childhood polycythemia vera and essential thrombocythemia.
Teofili L; Giona F; Martini M; Cenci T; Guidi F; Torti L; Palumbo G; Amendola A; Foà R; Larocca LM
J Clin Oncol; 2007 Mar; 25(9):1048-53. PubMed ID: 17369568
[TBL] [Abstract][Full Text] [Related]
6. Clinical and laboratory features, pathobiology of platelet-mediated thrombosis and bleeding complications, and the molecular etiology of essential thrombocythemia and polycythemia vera: therapeutic implications.
Michiels JJ; Berneman Z; Van Bockstaele D; van der Planken M; De Raeve H; Schroyens W
Semin Thromb Hemost; 2006 Apr; 32(3):174-207. PubMed ID: 16673274
[TBL] [Abstract][Full Text] [Related]
7. Venous thromboembolism in patients with essential thrombocythemia and polycythemia vera.
Reikvam H; Tiu RV
Leukemia; 2012 Apr; 26(4):563-71. PubMed ID: 22076463
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of interleukin-23 plasma levels in patients with polycythemia vera and essential thrombocythemia.
Gangemi S; Allegra A; Pace E; Alonci A; Ferraro M; Petrungaro A; Saitta S; Gerace D; Russo S; Penna G; Musolino C
Cell Immunol; 2012; 278(1-2):91-4. PubMed ID: 23121980
[TBL] [Abstract][Full Text] [Related]
9. Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments.
De Stefano V; Za T; Rossi E; Vannucchi AM; Ruggeri M; Elli E; Micò C; Tieghi A; Cacciola RR; Santoro C; Gerli G; Vianelli N; Guglielmelli P; Pieri L; Scognamiglio F; Rodeghiero F; Pogliani EM; Finazzi G; Gugliotta L; Marchioli R; Leone G; Barbui T;
Haematologica; 2008 Mar; 93(3):372-80. PubMed ID: 18268279
[TBL] [Abstract][Full Text] [Related]
10. JAK2V617F mutation and hydroxyurea treatment as determinants of immature platelet parameters in essential thrombocythemia and polycythemia vera patients.
Panova-Noeva M; Marchetti M; Buoro S; Russo L; Leuzzi A; Finazzi G; Rambaldi A; Ottomano C; Ten Cate H; Falanga A
Blood; 2011 Sep; 118(9):2599-601. PubMed ID: 21750318
[TBL] [Abstract][Full Text] [Related]
11. The acceleration of the propagation phase of thrombin generation in patients with steady-state sickle cell disease is associated with circulating erythrocyte-derived microparticles.
Gerotziafas GT; Van Dreden P; Chaari M; Galea V; Khaterchi A; Lionnet F; Stankovic-Stojanovic K; Blanc-Brude O; Woodhams B; Maier-Redelsperger M; Girot R; Hatmi M; Elalamy I
Thromb Haemost; 2012 Jun; 107(6):1044-52. PubMed ID: 22535498
[TBL] [Abstract][Full Text] [Related]
12. Platelet-mediated erythromelalgic, cerebral, ocular and coronary microvascular ischemic and thrombotic manifestations in patients with essential thrombocythemia and polycythemia vera: a distinct aspirin-responsive and coumadin-resistant arterial thrombophilia.
Michiels JJ; Berneman Z; Schroyens W; Koudstaal PJ; Lindemans J; Neumann HA; van Vliet HH
Platelets; 2006 Dec; 17(8):528-44. PubMed ID: 17127481
[TBL] [Abstract][Full Text] [Related]
13. Dkk3 levels in patients with myeloproliferative neoplasms.
Medinger M; Muesser P; Girsberger S; Skoda R; Tzankov A; Buser A; Passweg J; Tsakiris DΑ
Thromb Res; 2014 Feb; 133(2):218-21. PubMed ID: 24309205
[TBL] [Abstract][Full Text] [Related]
14. Reduction of antithrombin III, protein C, and protein S levels and activated protein C resistance in polycythemia vera and essential thrombocythemia patients with thrombosis.
Bucalossi A; Marotta G; Bigazzi C; Galieni P; Dispensa E
Am J Hematol; 1996 May; 52(1):14-20. PubMed ID: 8638606
[TBL] [Abstract][Full Text] [Related]
15. Uncontrolled thrombocytosis in polycythemia vera is a risk for thrombosis, regardless of JAK2(V617F) mutational status.
Ohyashiki K; Akahane D; Gotoh A; Ito Y; Tauchi T; Miyazawa K; Kimura Y; Ohyashiki JH
Leukemia; 2007 Dec; 21(12):2544-5. PubMed ID: 17611562
[No Abstract] [Full Text] [Related]
16. Correlative study between the JAK2V617F mutation and thrombosis in patients with myeloproliferative neoplasm.
Li ZC; Fu HJ; Wang ZM; Yang S; Xu HZ
Genet Mol Res; 2016 Aug; 15(3):. PubMed ID: 27706633
[TBL] [Abstract][Full Text] [Related]
17. Circulating Protein Disulfide Isomerase Is Associated with Increased Risk of Thrombosis in
Sharda AV; Bogue T; Barr A; Mendez LM; Flaumenhaft R; Zwicker JI
Clin Cancer Res; 2021 Oct; 27(20):5708-5717. PubMed ID: 34400417
[TBL] [Abstract][Full Text] [Related]
18. Increasing procoagulant activity of circulating microparticles in patients with Philadelphia-negative myeloproliferative neoplasms: a single-centre experience.
Kissova J; Ovesna P; Bulikova A; Zavřelova J; Penka M
Blood Coagul Fibrinolysis; 2015 Jun; 26(4):448-53. PubMed ID: 25828967
[TBL] [Abstract][Full Text] [Related]
19. Prediction of thrombotic and hemorrhagic events during polycythemia vera or essential thrombocythemia based on leukocyte burden.
Lim Y; Lee JO; Kim SH; Kim JW; Kim YJ; Lee KW; Lee JS; Bang SM
Thromb Res; 2015 May; 135(5):846-51. PubMed ID: 25743883
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of platelet function and pharmacological platelet inhibition in patients with myeloproliferative disorders using multiple electrode aggregometry.
Robier C; Neubauer M; Sternad H; Quehenberger F; Rainer F; Neumeister P
Thromb Res; 2010 Sep; 126(3):232-7. PubMed ID: 20630570
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
